AB Science SA (Euronext - FR0010557264 - AB) today announces publication of a peer-reviewed article titled ‘
Masitinib is a broad coronavirus 3CL inhibitor that effectively blocks replication of SARS-CoV-2 in the journal
Science [1]. The article reports on research that identifies masitinib as a broad antiviral agent capable of treating SARS-CoV-2 (the virus that causes COVID-19), including demonstration of
in vivo activity in mice, with efficacy maintained,
in vitro, against SARS-CoV-2 variants of concern.
This article and its accompanying online supplemental material are accessible online from the journal website: https://science.sciencemag.org/lookup/doi/10.1126/science.abg5827
Research led by Professor Savas Tay and Dr. Nir Drayman from the Pritzker School for Molecular Engineering (University of Chicago, USA) screened a library of 1,900 clinically safe drugs and identified masitinib as the most potent inhibitor of the main target responsible for virus reproduction,
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
AB Science announces that a new independent publication confirms that masitinib has anti-vital .
AB ScienceJanuary 25, 2021 GMT
NEW INDEPENDENT PUBLICATION CONFIRMS THAT MASITINIB HAS ANTI-VIRAL ACTIVITY AGAINST THE SARS-COV-2 VIRUS
IN VITRO AND IS A PROMISING CANDIDATE FOR TREATING COVID-19
Paris, 25 January 2021, 8.30am CET
AB Science SA (NYSE Euronext - FR0010557264 - AB) today announced the publication of preclinical study results with masitinib in COVID-19. Research led by scientists from the Institute of Human Virology (Guangzhou, China) has been published in the peer-reviewed journal
mBIO (a journal of the American Society for Microbiology). The article, entitled ‘Engineering a reliable and convenient SARS-CoV-2 replicon system for analysis of viral RNA synthesis and screening of antiviral inhibitors’,[1] is freely accessible online from the mBio journal site https://mb
Vers un médicament miracle contre le coronavirus ? financialafrik.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialafrik.com Daily Mail and Mail on Sunday newspapers.